We have heard from Howard Wolinksy that he and others have been helping to put together a series of four webinars on different aspects of active surveillance (AS) for the management of favorable-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, surveillance, webinar | 1 Comment »
A researcher at the Medical University of South Carolina (MUSC) College of Nursing is conducting a study to better understand supportive care needs and quality of life among individuals with ADVANCED forms of prostate cancer. If you live in the USA or its territories and are a patient with ADVANCED (i.e., recurrent, non-localized, or metastatic) prostate cancer, you are potentially eligible to participate. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: advanced, care, QOL, quality of life, supportive, survey | Leave a comment »
Perhaps unsurprisingly, it appears to be true that “AR gain” (see below) does indeed lower overall survival (OS) and progression-free survival (PFS) rates among men with castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, AR, ARSI, castration-resistant, CRPC, gain, inhibitor, receptor, signaling | 3 Comments »
So even if we don’t want to think or talk about it, most of us are well aware that about 40 percent of all Americans are now obese. In other words, they have a body mass index (BMI) of 30 kg/m2 or higher. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: BMI, body, index, mass, mortality, weight | Leave a comment »
The recommendations of the Philadelphia Prostate Cancer Consensus Conference 2019 (held in October last year) on implementation of germline testing for risk of prostate cancer have now been published in the Journal of Clinical Oncology. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: consensus, germline, risk, somatic, testing | 1 Comment »
Last month, we looked at Level 1 evidence (highest level, superseding all previous studies) that for unfavorable-risk patients, brachy boost therapy (BBT) — i.e., external beam therapy (EBRT) with a brachytherapy boost to the prostate — has better results when accompanied by 18 months of androgen deprivation therapy (ADT) (see this link). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, brachy boost, high, intermediate, radiation, risk, therapy | 2 Comments »
A company that is developing new forms of targeted treatment for late-stage prostate cancer is seeking some help from one or two members of the prostate cancer patient community. … READ MORE …
Filed under: Living with Prostate Cancer | Leave a comment »
The results of the Phase III HERO trial of relugolix — the first oral LHRH antagonist for treatment of advanced prostate cancer — have now been reported in the New England Journal of Medicine (NEJM) and at the “virtual” annual meeting of the American Society for Clinical Oncology (ASCO). … REAR MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, antiandrogen, HERO, LHRH, oral, relugolix, trial | 1 Comment »
So — rather obviously — the web has been swamped with information about COVID-19 over the past 2 months or more. That information runs the gamut from very accurate, well-constructed guidance to utter garbage, and it would have been impossible for us to sort it all out for you. So we haven’t tried. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: coronavirus, COVID-19, pandemic | 13 Comments »
At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, intermediate risk, low risk, Provenge, ProVent, sipuleucel-T, surveillance, trial | Leave a comment »
